High-dimensional profiling of pediatric immune responses to solid organ transplantation

Mahil Rao1, Meelad Amouzgar2, James T Harden3

  • 1Department of Pediatrics, Division of Pediatric Critical Care Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA; Transplant Immunology Lab, Stanford University School of Medicine, Palo Alto, CA 94304, USA.

Cell Reports. Medicine
|August 8, 2023
PubMed

Insights

Detecting early transplant rejection in children is challenging. This study reveals how immune cell changes in pediatric transplant recipients are linked to graft health, paving the way for better monitoring and treatments.

Area of Science:

  • Pediatric immunology
  • Transplant medicine
  • Single-cell analysis

Background:

  • Solid organ transplantation is vital for children with end-stage organ failure.
  • Acute rejection affects approximately 33% of pediatric allograft recipients within the first year.
  • Understanding immune changes in pediatric transplant recipients is crucial for early rejection detection.

Purpose of the Study:

  • To investigate the peripheral blood immune cell composition in pediatric solid organ transplant recipients.
  • To identify immune signatures associated with allograft health in children.
  • To explore organ-specific immune responses post-transplant.

Main Methods:

  • Detailed, multilineage, single-cell analysis using high-dimensional mass cytometry.
  • Application of supervised and unsupervised analysis methods to study cell-type proportions.
  • Focus on peripheral blood immune composition in pediatric transplant recipients.

Main Results:

  • The type of allograft significantly influences the post-transplant immune profile.
  • Graft health is associated with specific changes in T cell subpopulations.
  • Organ-specific differences in immune profiles were observed.

Conclusions:

  • Immune profiles in pediatric transplant recipients vary based on allograft type.
  • Distinct T cell subpopulations correlate with graft health.
  • These findings support the development of targeted immunosuppressive therapies and improved rejection monitoring.

Related Concept Videos